global-alert
global messaging alerts

Pharmaceutical Technology Webinar Follow-up: Part 3

template-parts/default.php

Single-Dose Drug Delivery Fill-Finish Facility that is Scalable, Flexible, and able to Deliver up to 45M Units Per Month Delivered within an Accelerated Timeline of Fewer Than 7 Months
Part 3 of Pharmaceutical Technology Post-Webinar Series

ApiJect committed to creating emergency temporary fill-finish capacity for up to 45M doses a month of a candidate COVID-19 vaccine on BFS lines by the end of 2020. All of these BFS-packaged doses could then be used, if necessary, in ApiJect Prefilled Injectors for scalable, single-dose delivery.

Pharmaceutical Technology Webinar Follow-up: Part 2

template-parts/default.php

Solving Drug Challenges with Innovation, BFS, and a Technology Platform to Create Drug
Delivery Systems
Part 2 of Pharmaceutical Technology Post-Webinar Series

Learn how ApiJect built its Technology Platform around BFS to create innovative drug delivery systems for the prefilled syringe market and other sterile liquid pharmaceutical delivery formats.

Pharmaceutical Technology Webinar Follow-up: Part 1

template-parts/default.php

BFS and Prefilled Syringes: A Solution for Complex Formulations
Part 1 of Pharmaceutical Technology Post-Webinar Series

Many countries, including the US, lack the necessary surge capacity to reliably fill-finish and deliver billions of incremental doses of injectable drugs and vaccines during bio-emergencies.

Special Feature: PFS & Parenteral Manufacturing: How COVID-19 Changed the Market

template-parts/default.php

Special Feature: PFS & Parenteral Manufacturing: How COVID-19 Changed the Market
Drug Development & Delivery, Issue: May 2021

Worldwide, the parenteral market is seeing greater emphasis on patient safety. This is driving a strong trend to­ward unit-dose formats, including Blow-Fill-Seal pre­filled syringe, which are now the fastest-growing format for injectables.